×

A group sequential test for treatment effect based on the Fine-Gray model. (English) Zbl 1414.62460

Summary: Competing risks endpoints arise when patients can fail therapy from several causes. Analyzing these outcomes allows one to assess directly the benefit of treatment on a primary cause of failure in a clinical trial setting. Regression models can be used in clinical trials to adjust for residual imbalances in patient characteristics, improving the power to detect treatment differences. But, none of the competing risks methods currently available for use in group sequential trials adjust for covariates. We propose a group sequential test for treatment effect that, because it is based on the Fine-Gray model [J. P. Fine and R. J. Gray, J. Am. Stat. Assoc. 94, No. 446, 496–509 (1999; Zbl 0999.62077)], permits adjustment for covariates. Our derivations show that its sequence of test statistics has an asymptotic distribution with an independent increments structure, which allows standard techniques such as O’Brien-Fleming designs and error spending functions to be employed to meet type I error rate and power specifications. We demonstrate the test in a reanalysis of BMT CTN 0402, a phase III clinical trial that evaluated an experimental treatment for the prevention of adverse outcomes following blood and marrow transplant. Moreover, using a simulation study of randomized group sequential trials, we demonstrate that the proposed method preserves the type I error rate and power at their nominal levels in the presence of influential covariates.

MSC:

62P10 Applications of statistics to biology and medical sciences; meta analysis
62J02 General nonlinear regression
62L10 Sequential statistical analysis

Citations:

Zbl 0999.62077
PDFBibTeX XMLCite
Full Text: DOI Link